Online inquiry

IVTScrip™ mRNA-Human ASB9, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK27501MR)

This product GTTS-WK27501MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the ASB9 protein. This product can be used in Retinoid acid signaling-responsive fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001031739.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 140462
UniProt ID Q96DX5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ASB9, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WK27501MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK19713MR IVTScrip™ mRNA-Human ANKRD27, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD27
GTTS-WK25620MR IVTScrip™ mRNA-Human ARHGEF4, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF4
GTTS-WK23473MR IVTScrip™ mRNA-Human ARFIP2, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ARFIP2
GTTS-WK7692MR IVTScrip™ mRNA-Human ADAM19, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADAM19
GTTS-WK2799MR IVTScrip™ mRNA-Human CD59, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD59
GTTS-WK12536MR IVTScrip™ mRNA-Human ADGRE1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADGRE1
GTTS-WK10392MR IVTScrip™ mRNA-Human ADAM19, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADAM19
GTTS-WK13159MR IVTScrip™ mRNA-Human ADORA2A, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADORA2A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW